STOCK TITAN
  1. Home
  2. News
  3. IMNN

Imunon Inc - IMNN STOCK NEWS

IMPACT
SENTIMENT
IMNN : Nasdaq
IMUNON Announces First Patient enrolled in Phase 1/2 Clinical Trial of IMNN-001 in Combination with bevacizumab in Advanced Ovarian Cancer
clinical trial
IMPACT
SENTIMENT
IMNN : Nasdaq
IMUNON Appoints Dr. Patrick Ott to its Scientific Advisory Board
management
IMPACT
SENTIMENT
IMNN : Nasdaq
IMUNON Reports Interim Progression-Free Survival and Overall Survival Data in Phase 1/2 OVATION 2 Study in Advanced Ovarian Cancer
clinical trial
IMPACT
SENTIMENT
IMNN : Nasdaq
IMUNON Releases Enterprise Video Highlighting the Company’s Mission, Vision, Values, Breakthroughs and Technologies
IMPACT
SENTIMENT
IMNN : Nasdaq
IMUNON Reminds Investors of its Virtual R&D Day Tomorrow at 4:00 p.m. ET
IMPACT
SENTIMENT
IMNN : Nasdaq
IMUNON to Host Virtual R&D Day on September 14th Beginning at 4:00 p.m. ET
conferences
IMPACT
SENTIMENT
IMNN : Nasdaq
IMUNON to Participate in the H.C. Wainwright Global Investment Conference
conferences
IMPACT
SENTIMENT
IMNN : Nasdaq
IMUNON Enters into CRADA for Preclinical Studies of PlaCCine Modality in Preventive Vaccines Against Lassa Virus
clinical trial
IMPACT
SENTIMENT
IMNN : Nasdaq
IMUNON Expands Scientific Advisory Board with the Addition of Dr. Sachet Shukla
management
IMPACT
SENTIMENT
IMNN : Nasdaq
IMUNON Reports Second Quarter 2023 Financial Results and Provides Business Update
earnings
Stock IMNN logo
Imunon Inc
Nasdaq:IMNN

IMNN Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link

About IMNN

celsion is a biopharmaceutical company dedicated to the research and development of innovative, targeted therapies that address unmet medical needs in oncology. with the recent acquisition of egen, inc., celsion has become a fully integrated company with an extensive, complementary, multi-phase clinical pipeline; platform technologies for the discovery of novel, nucleic acid-based immunotherapies and other anti-cancer dna/rna therapies; and expertise from bench to bedside.